WHO ICTRP trial
VANFLYTA Tablet Post-marketing Surveillance Study
JPRN-jRCT1080224910 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT1080224910 |
|---|---|
| Public title | VANFLYTA Tablet Post-marketing Surveillance Study |
| Scientific title | VANFLYTA Tablet Post-marketing Surveillance Study |
| Primary sponsor | DAIICHI SANKYO CO., LTD. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Observational |
| Countries | Japan |
| Conditions | Relapsed or refractory acute myeloid leukemia with FLT3-ITD mutation positive |
| Interventions | investigational material(s) Generic name etc : Quizartinib Hydrochloride INN of investigational material : quizartinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : For… |
| Registration date | Oct 10, 2019 |
| Target size | 210 |
| Secondary IDs | JapicCTI-194995 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: